Non Small Cell Lung Cancer
The most common type of lung cancer (~85% of cases), and a major arena for targeted and immune therapies.
If Non Small Cell Lung Cancer is on your watch list: what changed in the coverage, what the reporting asserts, and what the crowd is pricing.
What’s changed
- Integrated computational and preclinical evaluation of drug repurposing candidates for KRAS-mutant non-small cell lung cancer. · Sci Rep · 2026-08-13
- Anticancer effects of an XPO1 inhibitor (selinexor) with sotorasib following omeprazole preconditioning in KRAS G12C-mutant non-small cell lung cancer cells in · Neoplasia · 2026-08-17
- KRAS G12C-Targeted Therapy in Non-Small Cell Lung Cancer: From Resistant Salvage to Potential First-Line Backbone. · Int J Mol Sci · 2026-07-20
- Radio-sensitization of mutated KRAS G12C non-small cell lung cancer with KRAS G12C tyrosine kinase inhibitor and carbon ions irradiation. · Mol Cell Biochem · 2026-07-31